Evidence map›Paper›PMID 39891171›Full record

ArticleJournal of translational medicine2025

Tumor-derived exosomal lncRNA-MIR193BHG promotes bone metastasis of breast cancer by targeting the miR-489-3p/DNMT3A signaling axis in osteoclasts.

Xiaoya Liu, Rui Ma, Feng Wei, Maihuan Wang, Yiwei Jiang, Peng Zheng, Zhen Cao

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoya Liu *Department of General Surgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China.
Rui Ma *Department of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Feng Wei *Department of General Surgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China.
Maihuan WangDepartment of General Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Yiwei JiangDepartment of General Surgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China.
Peng ZhengDepartment of General Surgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China. zhengp0228@163.com.ORCID 0009-0006-5105-7850
Zhen CaoDepartment of General Surgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China. zhenyacy@163.com.

Funding

Innovative Research Group Project of the National Natural Science Foundation of China 82103507
6 · The paper itself

Abstract

backgroundBreast cancer exhibits high incidence and mortality among women, with distant metastasis, especially bone metastasis, being the leading cause of death. Despite advances in adjuvant therapies, bone metastasis remains a challenge for patient survival and quality of life. Exosomes, small vesicles capable of mediating intercellular communication, play a crucial role in tumor metastasis.

resultsThis study investigated the role of tumor-derived exosomal long noncoding RNA (lncRNA)-MIR193BHG in breast cancer bone metastasis. LncRNA-MIR193BHG was delivered to osteoclasts via exosomes and promoted osteoclast formation and activity by targeting the miR-489-3p/DNA methyltransferase 3A (DNMT3A) signaling axis, thereby accelerating breast cancer-induced osteolysis. Knockdown experiments demonstrated that reducing the levels of exosomal lncRNA-MIR193BHG significantly inhibited osteoclast differentiation and bone resorption, which was confirmed both in vitro and in vivo. Additionally, mechanistic studies revealed that lncRNA-MIR193BHG acted as a competitive endogenous RNA (ceRNA) interacting with miR-489-3p, regulating DNMT3A expression and subsequently affecting osteoclast differentiation.

conclusionsThese findings suggest that lncRNA-MIR193BHG plays a critical regulatory role in breast cancer bone metastasis, and the lncRNA-MIR193BHG/miR-489-3p/DNMT3A signaling axis could be a potential target for the treatment of breast cancer bone metastasis. Future studies should further explore the broader applicability of this mechanism and its clinical feasibility.

Indexed as

Bone NeoplasmsBreast NeoplasmsDNA (Cytosine-5-)-MethyltransferasesExosomesMicroRNAsOsteoclastsRNA, Long NoncodingSignal TransductionAnimalsBase SequenceBone ResorptionCell DifferentiationCell Line, TumorDNA Methyltransferase 3AFemaleGene Expression Regulation, NeoplasticDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanDnmt3a protein, mouseMicroRNAsRNA, Long NoncodingBreast cancer bone metastasisExosomesLncRNA

Identifiers

PMID39891171
PMCPMC11786480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.